0001209191-21-017237.txt : 20210303 0001209191-21-017237.hdr.sgml : 20210303 20210303182246 ACCESSION NUMBER: 0001209191-21-017237 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210301 FILED AS OF DATE: 20210303 DATE AS OF CHANGE: 20210303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Layman Melissa CENTRAL INDEX KEY: 0001806204 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36287 FILM NUMBER: 21711162 MAIL ADDRESS: STREET 1: C/O FLEXION THERAPEUTICS, INC. STREET 2: 10 MALL ROAD, STE. 301 CITY: BURLINGTON STATE: MA ZIP: 01803 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Flexion Therapeutics Inc CENTRAL INDEX KEY: 0001419600 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10 MALL ROAD STREET 2: SUITE 301 CITY: BURLINGTON STATE: MA ZIP: 01803 BUSINESS PHONE: (781) 305-7777 MAIL ADDRESS: STREET 1: 10 MALL ROAD STREET 2: SUITE 301 CITY: BURLINGTON STATE: MA ZIP: 01803 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-03-01 0 0001419600 Flexion Therapeutics Inc FLXN 0001806204 Layman Melissa C/O FLEXION THERAPEUTICS, INC. 10 MALL ROAD, SUITE 301 BURLINGTON MA 01803 0 1 0 0 Chief Commercial Officer Common Stock 2021-03-01 4 A 0 20100 0.00 A 108476 D Performance Restricted Stock Unit Award 0.00 2021-03-01 4 A 0 30150 0.00 A Common Stock 30150 30150 D Represents a restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan. Represents the maximum number of shares deliverable under the performance restricted stock unit award. Upon confirmation by the Board of Directors or the Compensation Committee thereof that a specified amount of 2021 revenues from ZILRETTA product sales is achieved, 25% of the shares eligible for vesting under the restricted stock unit award shall vest in 2022 upon confirmation of such revenues being achieved and thereafter on January 1 of the subsequent three years so that all of such shares will have vested on January 1, 2025. /s/ Mark S. Levine, Attorney-in-Fact 2021-03-03